Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 23Venous Thromboembolism 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Liposarcoma 1Leiomyosarcoma 1HR+HER2- Advanced Breast Cancer 1Glioblastoma 1Endometrial Neoplasms 1EGFR-mutant Non-small Cell Lung Cancer 1Cystadenocarcinoma, Serous 1Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies 1Colorectal Neoplasms 1Cardiovascular Diseases 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × EGFR-mutant Non-small Cell Lung Cancer × ribociclib × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡